Program
ponsegromab
Also written as “PF-06946860” and “Ponsegromab”.
In Pfizer's pipeline, Growth Differentiation Factor 15 (GDF15) monoclonal antibody
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Cachexia, led by Pfizer.
Furthest: phase 3, since May 7, 20258 company-led studies, 2 open or runningNext primary completion: Jan 23, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 82 open or running | phase 3since May 7, 2025 | Jul 17, 2018 | Jan 23, 2028phase 3 · NCT06989437 |
- Named in Pfizer’s own pipeline as
ponsegromab PF-06946860
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2018First study: phase 1 study in HealthyFirst studyNCT03599063 · 63 enrolled · United States
- Jun 3, 2019Phase 1 study in HealthyNCT03974776 · 8 enrolled · United States
- Feb 19, 2020Phase 1 study in CachexiaNCT04299048 · 11 enrolled · United States
- Mar 15, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04803305 · 18 enrolled · United States, Canada
- Aug 12, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05546476 · 187 enrolled · United States, Australia, Bulgaria and more
- Jan 5, 2023Phase 1 study in HealthyNCT05685264 · 18 enrolled · China
- May 7, 2025Phase 3 study in CachexiaNCT06989437 · 982 planned · United States, Australia, Belgium and more
- Jun 17, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07663630 · 80 planned · United States, China
Ahead
- Jan 23, 2028Primary completion: phase 3 study in CachexiaNCT06989437
- May 6, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07663630
TargetBeta
“Growth Differentiation Factor 15 (GDF15) monoclonal antibody”the company's pipeline, read by Claude · source
“A monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), with potential anti-cachexia activity. Upon administration, ponsegromab targets and binds to GDF15, thereby preventing the binding of GDF15 to its receptor glial-cell-derived neurotrophic factor (GDN…”NCIt, read by Claude
“A monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), ”NCIt, by rule
Other programs on GDF15
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| visugromabrule | catalym-gmbh | phase 3 | 6 |
| rilogrotugrule | LG Chem | phase 3 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07663630Carcinoma, Non-Small-Cell Lung · United States, China | 1 | Not yet recruiting | May 6, 2028 | 80 |
| NCT06989437Cachexia · United States, Australia, Belgium and more | 3 | Recruiting | Jan 23, 2028 | 982 |
| NCT05685264Healthy · China | 1 | Completed | Jul 7, 2023 | 18 |
| NCT05546476Carcinoma, Non-Small-Cell Lung · United States, Australia, Bulgaria and more | 2 | Completed | Mar 13, 2024 | 187 |
| NCT04803305Carcinoma, Non-Small-Cell Lung · United States, Canada | 1 | Completed | Apr 14, 2022 | 18 |
| NCT04299048Cachexia · United States | 1 | Completed | Mar 30, 2022 | 11 |
| NCT03974776Healthy · United States | 1 | Completed | Jan 10, 2020 | 8 |
| NCT03599063Healthy · United States | 1 | Completed | Sep 18, 2019 | 63 |
How it is read
Names in the registry
- “PF-06946860”, 4 entries
- “ponsegromab”, 3 entries
- “Ponsegromab”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Cachexia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.